FXR activation has been reported to reduce renal overexpression of SREBP-1 and lipogenic enzymes as well as decreasing lipid accumulation in mouse models of diabetes (65) and obesity (60), thereby acting to reduce profibrotic factors. Here, NR1H4 is linked to obesity disorder.